Email: cspc@cspc.cn
News
September 20, 2024
Share:
Previous: VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA
Next: VOLUNTARY ANNOUNCEMENT AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us